Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rose Pharma Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being handled within a distinct art unit, reflecting a focused prosecution effort. The portfolio involves 1 distinct examiner, SABILA, MERCY HELLEN, who is responsible for the pending action.
The alignment of the pending office action with a single examiner and a single art unit simplifies the management of this intellectual property. Since SABILA, MERCY HELLEN is the only examiner involved, the company's current prosecution success depends entirely on the interactions within this specific Biotechnology & Pharmaceuticals classification.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19208126 | GLP-1 FORMULATIONS AND THEIR USES | SABILA, MERCY HELLEN | 66d overdue |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19208126 | GLP-1 FORMULATIONS AND THEIR USES | SABILA, MERCY HELLEN | 1654 | §103 | Final Rejection | 66d overdue | Pending | May 14, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial